ReviewExpert review of vaccines2012
Chikungunya virus and prospects for a vaccine.
Review in Expert review of vaccines, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of chronic comorbidities in chikungunya: A systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2018Pooled it
- Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.Lancet (London, England) · 2023Trial
- Structural and immunogenic characterisation of ChAdOx1 Chik-derived Chikungunya VLPs supports a mechanistic rationale for vaccine-induced protection.Npj viruses · 2026Article
- Maturation-deficient chikungunya virus elicits protective immune responses in a murine challenge model.NPJ vaccines · 2026Article
- Anti-chikungunya Activity of a Cinnamic Acid Derivative: An In Vitro and In Silico Study.Molecular biotechnology · 2026Article
- A subunit vaccine protects A129 mice from death and joint swelling against lethal Chikungunya virus challenge.Frontiers in immunology · 2026Article
- Antiviral Activity of Synthetic Bis-Naphthoquinone (H-5) against Chikungunya Virus Replication.Current topics in medicinal chemistry · 2026Article
- The impact of variations in the chikungunya genome on the clinical manifestations and transmission of the disease.Journal of family medicine and primary care · 2025Review
- Modeling within-host Chikungunya virus dynamics with the immune system using semi-analytical approaches.BMC research notes · 2025Article
- Highly Potent Neutralizing Nanobodies Acting Against Chikungunya Virus Infection via Inhibiting Multiple Stages of the Viral Life Cycle.International journal of molecular sciences · 2025Article
- Infectomics of Chikungunya Virus: Roles Played by Host Factors.The American journal of tropical medicine and hygiene · 2025Review
- Immunogenic recombinant Mayaro virus-like particles present natively assembled glycoprotein.NPJ vaccines · 2024Article
- Article
- The risk and risk factors of chikungunya virus infection and rheumatological sequelae in a cohort of U.S. Military Health System beneficiaries: Implications for the vaccine era.PLoS neglected tropical diseases · 2024Article
- Co-circulation of two Alphaviruses in Burkina Faso: Chikungunya and O'nyong nyong viruses.PLoS neglected tropical diseases · 2024Article
- Dengue Virus and Zika Virus Seroprevalence in the South Pacific Populations of the Cook Islands and Vanuatu.Viruses · 2024Article
- Single-Dose Immunogenic DNA Vaccines Coding for Live-Attenuated Alpha- and Flaviviruses.Viruses · 2024Review
- Unraveling the complex interplay: immunopathology and immune evasion strategies of alphaviruses with emphasis on neurological implications.Frontiers in cellular and infection microbiology · 2024Review
- Therapeutic potential of salicylamide derivatives for combating viral infections.Medicinal research reviews · 2023Review
- The protein disulfide isomerase inhibitor 3-methyltoxoflavin inhibits Chikungunya virus.Bioorganic & medicinal chemistry · 2023Article
54 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
In 2004, chikungunya virus (CHIKV) re-emerged from East Africa to cause devastating epidemics of debilitating and often chronic arthralgia that have affected millions of people in the Indian Ocean Basin and Asia. More limited epidemics initiated by travelers subsequently occurred in Italy and France, as well as human cases exported to most regions of the world, including the Americas where CHIKV could become endemic. Because CHIKV circulates during epidemics in an urban mosquito-human cycle, control of transmission relies on mosquito abatement, which is rarely effective. Furthermore, there is no antiviral treatment for CHIKV infection and no licensed vaccine to prevent disease. Here, we discuss the challenges to the development of a safe, effective and affordable chikungunya vaccine and recent progress toward this goal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.